A Randomized Phase II Study of Venetoclax and HMA-based Therapies for theTreatment of Older and Unfit Adults With Newly Diagnosed for FLT-3 Mutated Acute Myeloid Leukemia (AML): a MyeloMATCH Treatment Trial
- Sponsor:
- ECOG-ACRIN Cancer Research Group
- Sponsor Study ID:
- MM1OA-EA02
- CTO #:
- 104105
- NCT Number:
- NCT06317649
- Phase:
- II
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Myeloid and Monocytic Leukemia
- Study Objectives:
- To compare the achievement rate of MRDneg CR of either triplet regimen to azacitidine and venetoclax alone within 4 cycles of therapy
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Baratam, Praneeth, at baratamp@musc.edu .
- Study Coordinator, Baker, Hana, at bakerhan@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina